Format

Send to

Choose Destination
J Neuroimmunol. 2016 Dec 15;301:30-34. doi: 10.1016/j.jneuroim.2016.10.011. Epub 2016 Nov 9.

Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis.

Author information

1
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan. Electronic address: neuiwasa@med.kanazawa-u.ac.jp.
2
Department of Neurology, National Hospital Organization Ishikawa Hospital, sa-150 Teduka-machi, Kaga 922-0405, Japan. Electronic address: furukawa@med.kanazawa-u.ac.jp.
3
Health Service Center, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Electronic address: hiroaki@staff.kanazawa-u.ac.jp.
4
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan. Electronic address: m-yamada@med.kanazawa-u.ac.jp.

Abstract

Caveolin-3 is a muscle-specific membrane protein that localizes to the sarcolemma and T-tubule system. Caveolin-3 is needed for muscle repair and skeletal muscle development. The objective of this study was to compare caveolin-3 expression in myasthenia gravis (MG) and control muscles. Caveolin-3 was abnormally expressed in the MG muscle membrane, with partial loss of expression and overexpression in 5/15 and 10/15 patients, respectively. Caveolin-3 mRNA and protein levels were higher in MG than in control muscles, suggesting that partial deficiency of caveolin-3 is occasionally detected in MG muscle and that caveolin-3 overexpression may be required after MG muscle damage.

KEYWORDS:

Caveolin-3; Myasthenia gravis; Skeletal muscle; qRT-PCR

PMID:
27863830
DOI:
10.1016/j.jneuroim.2016.10.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center